secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070294
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Q1 net loss $23.7M, cash $42.1M; REMAIN-1 pivotal enrollment complete
--------------------------------------------------------------------------------

- Net loss $23.7M vs $3.3M YoY, driven by non-cash fair value change and $3.2M operating expense increase.
- Cash $42.1M expected to fund operations into Q4 2025; R&D expenses rose to $19.4M from $14.4M.
- REMAIN-1 Pivotal Cohort (315 patients) enrollment completed ahead of schedule; 6-month primary endpoint data H2 2026.
- REVEAL-1 3-month open-label data update expected June 2025; REMAIN-1 Midpoint Cohort data Q3 2025.
- Rejuva gene therapy advancing; first CTA module submission for RJVA-001 expected June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025070294/0000950170-25-070294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025070294/guts-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer